DMPK and myotonic dystrophy type 1: To complete these studies, a quantitative methylation method at each CpG site of the DMPK locus coupled with a detailed analysis of patient phenotypes in a large DM1 cohort is crucial to validate DNA methylation as biomarker for specific symptoms.